• 1
    von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
  • 2
    Nicholson RI, Gee JMW, Harper ME. EGFR and cancer prognosis. Eur J Cancer. 2001;37:S9-S15.
  • 3
    Chow NH, Liu HS, Lee EI, et al. Significance of urinary epidermal growth factor and its receptor expression in human bladder cancer. Anticancer Res. 1997;17:1293-1296.
  • 4
    Salomon DS, Brandt R, Ciardiello F, et al. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol. 1995;19:183-232.
  • 5
    Wells A. Tumor invasion: role of growth factor-induced cell motility. Adv Cancer Res. 2000;78:31-101.
  • 6
    Eccles SA. Cell biology of lymphatics metastasis. The potential role of c-erbB oncogene signaling. Recent Results Cancer Res. 2000;157:41-54.
  • 7
    Nguyen PL, Swanson PE, Jaszcz W, et al. Expression of epidermal growth factor receptor in invasive transitional cell carcinoma of the urinary bladder. A multivariate survival analysis. Am J Clin Pathol. 1994;101:166-176.
  • 8
    Neal DE, Marsh C, Bennett MK, et al. Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours. Lancet. 1985;1:366-368.
  • 9
    Neal DE, Sharples L, Smith K, et al. The epidermal growth factor receptor and the prognosis of bladder cancer. Cancer. 1990;65:1619-1625.
  • 10
    Messing EM. Clinical implications of the expression of epidermal growth factor receptors in human transitional cell carcinoma. Cancer Res. 1990;50:2530-2537.
  • 11
    Bue P, Wester K, Sjostrom A, et al. Expression of epidermal growth factor receptor in urinary bladder cancer metastases. Int J Cancer. 1998;76:189-193.
  • 12
    Lipponen P, Eskelinen M. Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis. Br J Cancer. 1994;69:1120-1125.
  • 13
    Kramer C, Klasmeyer K, Bojar H, et al. Heparin-binding epidermal growth factor-like growth factor isoforms and epidermal growth factor receptor/ErbB1 expression in bladder cancer and their relation to clinical outcome. Cancer. 2007;109:2016-2024.
  • 14
    Mellon K, Wright C, Kelly P, et al. Long-term outcome related to epidermal growth factor receptor status in bladder cancer. J Urol. 1995;153:919-925.
  • 15
    Kroft SH, Oyasu R. Urinary bladder cancer: mechanisms of development and progression. Lab Invest. 1994;71:158-174.
  • 16
    Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49:4682-4689.
  • 17
    Kompier LC, Lurkin I, van der Aa MN, et al. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy. PLoS One. 2010;5:e13821.
  • 18
    Visvanathan KV, Pocock RD, Summerhayes IC. Preferential and novel activation of H-ras in human bladder carcinomas. Oncogene Res. 1988;3:77-86.
  • 19
    Karimianpour N, Mousavi-Shafaei P, Ziaee AA, et al. Mutations of RAS gene family in specimens of bladder cancer. Urol J. 2008;5:237-242.
  • 20
    Munk M, Memon AA, Nexo E, et al. Inhibition of the epidermal growth factor receptor in bladder cancer cells treated with the DNA-damaging drug etoposide markedly increases apoptosis. BJU Int. 2007;99:196-201.
  • 21
    McHugh LA, Kriajevska M, Mellon JK, et al. Combined treatment of bladder cancer cell lines with lapatinib and varying chemotherapy regimens—evidence of schedule-dependent synergy. Urology. 2007;69:390-394.
  • 22
    Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med. 2006;354:567-578.
  • 23
    Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med. 2004;351:337-345.
  • 24
    Perrotte P, Matsumoto T, Inoue K, et al. Anti-epidermal growth factor receptor antibody C225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice. Clin Cancer Res. 1999;5:257-265.
  • 25
    Black PC, Brown GA, Inamoto T, et al. Sensitivity to epidermal growth factor receptor inhibitor requires E-cadherin expression in urothelial carcinoma cells. Clin Cancer Res.2008;14:1478-1486.
  • 26
    Grabowska MM, Sandhu B, Day ML. EGF promotes the shedding of soluble E-cadherin in an ADAM10-dependent manner in prostate epithelial cells. Cell Signal. 2012;24:532-538.
  • 27
    Zuo JH, Zhu W, Li MY, et al. Activation of EGFR promotes squamous carcinoma SCC10A cell migration and invasion via inducing EMT-like phenotype change and MMP-9-mediated degradation of E-cadherin. J Cell Biochem. 2011;112:2508-2517.
  • 28
    Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 2000;92:205-216.
  • 29
    Simon R, Wittes RE, Ellenberg SS. Randomized phase II clinical trials. Cancer Treat Rep. 1985;69:1375-1381.
  • 30
    Botten J, Sephton M, Tillett T, et al. Thromboembolic events with cisplatin-based neoadjuvant chemotherapy for transitional cell carcinoma of urinary bladder. J Clin Oncol. 2013;31(suppl 6):277.
  • 31
    Pessino A, Artale S, Sciallero S, et al. First-line single-agent cetuximab in patients with advanced colorectal cancer. Ann Oncol. 2008;19:711-716.
  • 32
    Petrelli F, Cabiddu M, Borgonovo K, et al. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials. Ann Oncol. 2012;23:1672-1679.
  • 33
    Hahn NM, Stadler WM, Zon RT, et al. Phase II trial of cisplatin, gemcitabine, and bevacizumab as first-line therapy for metastatic urothelial carcinoma: Hoosier Oncology Group GU 04-75. J Clin Oncol. 2011;29:1525-1530.
  • 34
    Ross J, Wang K, Al-Rohil RN, et al. Advanced urothelial carcinoma: next-generation sequencing reveals diverse genomic alterations and targets of therapy. Mod Pathol. 2014;27:271-280.
  • 35
    Iyer G, Al-Ahmadie H, Schultz N, et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J Clin Oncol. 2013;31:3133-3140.
  • 36
    Wong YN, Litwin S, Vaughn D, et al. Phase II trial of cetuximab with or without paclitaxel in patients with advanced urothelial tract carcinoma. J Clin Oncol. 2012;30:3545-3551.
  • 37
    Wulfing C, Machiels JP, Richel DJ, et al. A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma. Cancer. 2009;115:2881-2890.
  • 38
    Petrylak DP, Tangen CM, Van Veldhuizen PJ Jr, et al. Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium. BJU Int. 2010;105:317-321.
  • 39
    Philips GK, Halabi S, Sanford BL, et al. A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102. Ann Oncol. 2009;20:1074-1079.
  • 40
    Wheeler DL, Huang S, Kruser TJ, et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene. 2008;27:3944-3956.
  • 41
    Tsai YS, Cheng HL, Tzai TS, et al. Clinical significance of ErbB receptor family in urothelial carcinoma of the bladder: a systematic review and meta-analysis. Adv Urol. 2012;2012:181964.
  • 42
    Grivas PD, Day KC, Karatsinides A, et al. Evaluation of the anti-tumor activity of dacomitinib in models of human bladder cancer. Mol Med. 2013;19:367-376.
  • 43
    Figueroa JD, Ye Y, Siddiq A, et al. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet. 2014;23:1387-1398.
  • 44
    Solomon DA, Kim JS, Bondaruk J, et al. Frequent truncating mutations of STAG2 in bladder cancer. Nat Genet. 2013;45:1428-1423.
  • 45
    Guo G, Sun X, Chen C, et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat Genet. 2013;45:1459-1463.
  • 46
    Ross JS, Wang K, Gay L, et al. A high frequency of activating extracellular domain ERBB2 (HER2) mutation in micropapillary urothelial carcinoma. Clin Cancer Res. 2014;20:68-75.
  • 47
    Omran OM. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma. J Environ Pathol Toxicol Oncol. 2012;31:203-212.
  • 48
    Reis ST, Leite KR, Mosconi Neto A, et al. Immune expression of E-cadherin and α, β and γ-catenin adhesion molecules and prognosis for upper urinary tract urothelial carcinomas. Int Braz J Urol. 2012;38:466-473.
  • 49
    Khorrami MH, Hadi M, Gharaati MR, et al. E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection. Urol J. 2012;9:581-585.
  • 50
    Cui D, Han BM, Jing YF, et al. Analysis of N-E cadherin switch as an independent predictive parameter of bladder cancer survival outcomes [in Chinese]. Zhonghua Yi Xue Za Zhi. 2012;92:380-383.
  • 51
    Muramaki M, Miyake H, Terakawa T, et al. Expression profile of E-cadherin and N-cadherin in non-muscle-invasive bladder cancer as a novel predictor of intravesical recurrence following transurethral resection. Urol Oncol. 2012;30:161-166.
  • 52
    Erdemir F, Ozcan F, Kilicaslan I, et al. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma. Int Urol Nephrol. 2007;39:1031-1037.
  • 53
    Byrne RR, Shariat SF, Brown R, et al. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001;165:1473-1479.
  • 54
    Hu X, Ruan Y, Cheng F, et al. p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance. Int J Urol. 2011;18:630-637.
  • 55
    Shariat SF, Pahlavan S, Baseman AG, et al. E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001;57:60-65.
  • 56
    Serdar A, Turhan C, Soner G, et al. The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients. Int Urol Nephrol. 2005;37:485-492.
  • 57
    Mahnken A, Kausch I, Feller AC, et al. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder. Oncol Rep. 2005;14:1065-1070.
  • 58
    Fromont G, Roupret M, Amira N, et al. Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma. Eur Urol. 2005;48:764-770.
  • 59
    Kashibuchi K, Tomita K, Schalken JA, et al. The prognostic value of E-cadherin, alpha-, beta-, and gamma-catenin in urothelial cancer of the upper urinary tract. Eur Urol. 2006;49:839-845.
  • 60
    Mialhe A, Louis J, Montlevier S, et al. Expression of E-cadherin and alpha-, beta- and gamma-catenins in human bladder carcinomas: are they good prognostic factors? Invasion Metastasis. 1997;17:124-137.
  • 61
    Matsumoto K, Shariat SF, Casella R, et al. Preoperative plasma soluble E-cadherin predicts metastases to lymph nodes and prognosis in patients undergoing radical cystectomy. J Urol. 2003;170(pt 1):2248-2252.